RINVOQ® Upadacitinib 30 mg Tablet 30 Tablets

Name: Janus Kinase (JAK) Inhibitor
Brand: RINVOQ®

RINVOQ ER, TAB 30MG (30/EA)

McKesson #

1205936

Manufacturer #

00074231030

Brand

RINVOQ®

Manufacturer

AbbVie Inc

Country of Origin

Unknown

Application

Janus Kinase (JAK) Inhibitor

Container Type

Bottle

Dosage Form

Tablet

Generic Drug Code

51719

Generic Drug Name

Upadacitinib

NDC Number

00074231030

Product Dating

McKesson Acceptable Dating: we will ship >= 90 days

Quantity

30 Tablets

Strength

30 mg

Type

Extended Release

UNSPSC Code

51381700

RINVOQ® (upadacitinib) a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers
RINVOQ is indicated for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers
RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable